Plasmapheresis in myeloma cast nephropathy

Clinical Nephrology

Volumn 79, Issue 1, 2013, Pages 72-77

  Chapdelaine, Isabelle ^a,b   Madore, François ^b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

Author keywords

Cast nephropathy; Multiple myeloma; Plasma exchange; Plasmapheresis; Renal failure

Indexed keywords

BENCE JONES PROTEIN; BETA 2 MICROGLOBULIN; BORTEZOMIB; CREATININE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FRESH FROZEN PLASMA; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; MELPHALAN; STEROID; VINCRISTINE;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; COLLOID; CREATININE BLOOD LEVEL; CRYSTALLOID; DISEASE DURATION; DIURESIS; ECHOGRAPHY; HUMAN; HUMAN TISSUE; HYDRATION; KIDNEY BIOPSY; KIDNEY DISEASE; LOW BACK PAIN; MALE; MULTIMODALITY CANCER THERAPY; MYELOMA; MYELOMA CAST NEPHROPATHY; OSTEOLYSIS; PLASMACYTOSIS; PLASMAPHERESIS; PROGNOSIS; PROTEIN BLOOD LEVEL; RENAL REPLACEMENT THERAPY; TREATMENT DURATION; TREATMENT RESPONSE;

BIOPSY; HUMANS; KIDNEY DISEASES; KIDNEY TUBULES; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PLASMAPHERESIS;

EID: 84873703231     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN107064     Document Type: Article

References (22)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009; 59: 225-249. doi:10.3322/caac.20006
2. Bladé J, Fernández-Llama P, Bosch F, Montolíu J, Lens XM, Montoto S, Cases A, Darnell A, Rozman C, Montserrat E. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med. 1998; 158: 1889-1893. doi: 10.1001/archinte.158.17.1889
3. Montseny J-J, Kleinknecht D, Meyrier A, Vanhille P, Simon P, Pruna A, Eladari D. Long-term outcome according to renal histological lesions in 118 patients with monoclonal gammopathies. Nephrol Dial Transplant. 1998; 13: 1438-1445. doi:10.1093/ndt/13.6.1438
4. Rota S, Mougenot B, Baudouin B, De Meyer-Brasseur M, Lemaitre V, Michel C, Mignon F, Rondeau E, Vanhille P, Verroust P, Ronco P. Multiple myeloma and severe renal failure: a clinicopathologic study of outcome and prognosis in 34 patients. Medicine (Baltimore). 1987; 66: 126-137.
5. Iványi B. Frequency of light chain deposition nephropathy relative to renal amyloidosis and Bence Jones cast nephropathy in a necropsy study of patients with myeloma. Arch Pathol Lab Med. 1990; 114: 986-987.
6. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Larson DR, Plevak ME, Therneau TM, Greipp PR. Review of 1,027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003; 78: 21-33. doi:10.4065/78.1.21
7. Knudsen LM, Hippe E, Hjorth M, Holmberg E, Westin J; The Nordic Myeloma Study Group. Renal function in newly diagnosed multiple myeloma -a demographic study of 1353 patients. Eur J Haematol. 1994; 53: 207-212. doi:10.111 1/j.16 00-0609.1994.tb00190.x
8. Sanders PW, Herrera GA, Kirk KA, Old CW, Galla JH. Spectrum of glomerular and tubulointerstitial renal lesions associated with monotypical immunoglobulin light chain deposition. Lab Invest. 1991; 64: 527-537.
9. Fassas AB, Desikan KR, Siegel D, Golper TA, Munshi NC, Barlogie B, Tricot G. Tumour lysis syndrome complicating high-dose treatment in patients with multiple myeloma. Br J Haematol. 1999; 105: 938-941. doi:10.1046/j.1365-2141. 19 9 9 .01467.x
10. Dimopoulos MA, Kastritis E, Rosinol L, Bladé J, Ludwig H. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia. 2008; 22: 1485-1493. doi:10.1038/leu.2008.131
11. Markowitz GS, Appel GB, Fine PL, Fenves AZ, Loon NR, Jagannath S, Kuhn JA, Dratch AD, D'Agati VD. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol. 2001; 12: 1164-1172.
12. Markowitz GS, Fine PL, Stack JI, Kunis CL, Radhakrishnan J, Palecki W, Park J, Nasr SH, Hoh S, Siegel DS, D'Agati VD. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int. 2003; 64: 281-289. doi:10.1046/j.1523-1755.2003.00071.x
13. Bladé J, López-Guillermo A, Bosch F, Cervantes F, Reverter JC, Montserrat E, Rozman C. Impact of response to treatment on survival in multiple myeloma: results in a series of 243 patients. Br J Haematol. 1994; 88: 117-121. doi:10.1111/j. 136 5-2141.1994.tb04986.x
14. Brecher ME. Plasma exchange: why we do what we do. J Clin Apher. 2002; 17: 207-211. doi:10.1002/jca.10041
15. Mokrzycki MH, Kaplan AA. Therapeutic plasma exchange: complications and management. Am J Kidney Dis. 1994; 23: 817-827.
16. Shemin D, Briggs D, Greenan M. Complications of therapeutic plasma exchange: a prospective study of 1,727 procedures. J Clin Apher. 2007; 22: 270-276. doi:10.1002/jca.20143
17. Zucchelli P, Pasquali S, Cagnoli L, Ferrari G. Controlled plasma exchange trial in acute renal failure due to multiple myeloma. Kidney Int. 1988; 33: 1175-1180. doi:10.1038/ki.1988.127
18. Johnson WJ, Kyle RA, Pineda AA, O'Brien PC, Holley KE. Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy. Arch Intern Med. 1990; 150: 863-869. doi:10.1001/archinte.150.4.863
19. Clark WF, Stewart AK, Rock GA, Sternbach M, Sutton DM, Barrett BJ, Heidenheim AP, Garg AX, Churchill DN; Canadian Apheresis Group. Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med. 2005; 143: 777-784.
20. McLeod BC, Viernes AL, Sassetti RJ. Serum-free light chain analysis by crossed immunoelectrophoresis: correlation with plasmapheresis in light chain disease nephropathy. Am J Hematol. 1983; 15: 75-88. doi:10.1002/ajh.2830150109
21. Cserti C, Haspel R, Stowell C, Dzik W. Lightchain removal by plasmapheresis in myeloma-associated renal failure. Transfusion. 2007; 47: 511-514. doi:10.1111/j.1537-2995.2006.01143.x
22. Hutchison CA, Bradwell AR, Cook M, Basnayake K, Basu S, Harding S, Hattersley J, Evans ND, Chappel MJ, Sampson P, Foggensteiner L, Adu D, Cockwell P. Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol. 2009; 4: 745-754. doi:10.2215/ CJN.04590908